Blogs
E HIV Cure Challenger CytoDyn Takes On The Gilead Sciences
Article By:
Moon Kil Woong
Read
Friday, July 3, 2020 11:10 AM EDT
CytoDyn Inc. announced in a Proactive Investors video a major advancement in HIV whose message that may have gotten buried due to a lengthy disclosure about a fake new article that was promulgated by short seller Citron Research.
Markets Rise On Vaccine Hopes, US Jobs Figures Revised Up
Article By:
Adam Vettese
Read
Thursday, July 2, 2020 6:33 AM EDT
Markets have opened higher this morning as a joint venture Covid vaccine by Pfizer and Germany’s BioNTech was found to have promising results in early human trials. European bourses are up 1-2% with Germany’s Dax leading the way.
In this article: GM, PFE, BNTX, APA, GPS, TM, HRGLF, ITVPY, TWODF, AMZN, NFLX, DIA, SPY, COMP, FB, FCAU, PYPL, POYYF
Pedal To The Metal Leads To Record Rebound
Article By:
Wade Slome
Read
Thursday, July 2, 2020 3:23 AM EDT
Like a race car pushing the pedal to the metal, the stock market sped to its best quarterly stock market gains in decades. The +20% rebound in the 2nd quarter S&P 500 index was the best result achieved since 1998.
E Market Briefing For Wednesday, July 1
Article By:
Gene Inger
Read
Wednesday, July 1, 2020 2:08 AM EDT
The S&P finished it's best Quarter in about 20 years! We're honored that we have essentially been 'long and strong' the entire Quarter, reversing from the bearish stance we adopted in late January / early February, to enthusiastic Bulls.
In this article: MRK
Gilead Will Charge More Than $3,000 For A Course Of COVID-19 Drug Remdesivir
Article By:
Tyler Durden
Read
Monday, June 29, 2020 8:01 AM EDT
Gilead disclosed its pricing plan for Gilead as it prepares to begin charging for the drug at the beginning of next month (several international governments have already placed orders).
In this article: GILD
8 Stock Catalysts For The Week Ahead
Pending Clinical Readouts In Focus During A Short Holiday Week
Article By:
Benzinga
Read
Sunday, June 28, 2020 3:03 PM EDT
Biotech stocks went on a seesaw ride along with the broader markets in the week ending June 26. Yet, there were some encouraging developments on the COVID-19 vaccine development front. Vaccine companies are going all out.
In this article: SNY, TBIO, VXRT, ALXN, NVAX, RVNC, ITCI, ZYNE, OBSV, ITRM, NVS, CERC, RGNX, BNTX, INO, CDMO, CALT
Notable Insider Buys: Continental Resources, Fox, Groupon And More
Article By:
Benzinga
Read
Saturday, June 27, 2020 7:24 PM EDT
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit. So insider buying can be an encouraging signal for potential investors.
Week In Review: VistaGen Out-Licenses China/Asia Rights For Novel Anxiety Drug To EverInsight In $177 Million Deal
Article By:
ChinaBio® Today
Read
Saturday, June 27, 2020 2:00 PM EDT
VistaGen of South San Francisco out-licensed China/Southeast Asia rights for a novel anxiety treatment to EverInsight Therapeutics, a China in-licensing company, in a $177 million agreement.
3 Stocks To Buy As Companies Speed Up Vaccine Production
Article By:
Zacks Investment Research
Read
Friday, June 26, 2020 9:38 AM EDT
Pharmaceutical giants are speeding up vaccine development for the novel coronavirus. Although the FDA is yet to approve drug companies have already started ramping up manufacturing lines to meet global demand.